Labcorp Holdings Inc.

Equities

LH

US5049221055

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 13:47:01 2024-07-16 EDT			5-day change	1st Jan Change
214.2 ^USD	+3.25%		+7.27%	-5.92%

07-15	UBS Cuts Laboratory Corp of America Price Target to $260 From $262, Maintains Buy Rating	MT
07-09	Evercore ISI Adjusts Price Target on Laboratory Corp of America Holdings to $215 From $210	MT

Laboratory Corporation of America Holdings to Acquire Assets of Mount Sinai Health System Clinical Outreach Laboratories

January 10, 2017 at 08:30 am

Laboratory Corporation of America® Holdings and the Mount Sinai Health System have entered into a definitive agreement for LabCorp to acquire assets of Mount Sinai’s Clinical Outreach Laboratories. When the transaction is complete, LabCorp will be available to provide comprehensive laboratory services to physicians and patients that currently use Mount Sinai’s outreach laboratory.

Latest news about Labcorp Holdings Inc.

UBS Cuts Laboratory Corp of America Price Target to $260 From $262, Maintains Buy Rating	07-15	MT
Evercore ISI Adjusts Price Target on Laboratory Corp of America Holdings to $215 From $210	07-09	MT
Baird Raises Price Target on Laboratory Corp of America to $261 From $258	07-05	MT
Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials	06-17	CI
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $258 From $256	06-13	MT
HSBC Adjusts Price Target on Laboratory Corp of America Holdings to $210 From $225, Keeps Hold Rating	06-05	MT
Transcript : Labcorp Holdings Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 02:00 PM	06-04
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio	06-03	CI
JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261	05-30	MT
Some of the biggest splits in Corporate America	05-23	RE
Declaration of Voting Results by Laboratory Corporation of America Holdings	05-16	CI
Declaration of Voting Results by Laboratory Corporation of America Holdings	05-16	CI
Declaration of Voting Results by Laboratory Corporation of America Holding	05-16	CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing	05-16	MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating	05-16	MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy	05-15	CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal	05-06	CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021.	04-30	CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244	04-30	MT
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy	04-29	MT
US FDA publishes final rule for laboratory developed tests	04-29	RE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B	04-29	CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255	04-26	MT
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234	04-26	MT
Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating	04-26	MT

Chart Labcorp Holdings Inc.

Duration

Period

More charts

Company Profile

Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Ratings for Labcorp Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

207.5 USD

Average target price

238 USD

Spread / Average Target

+14.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
LABCORP HOLDINGS INC.	-5.92%	17.49B
HCA HEALTHCARE, INC.	+17.46%	83.02B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.85%	26.5B
FRESENIUS SE & CO. KGAA	+5.31%	17.72B
QUEST DIAGNOSTICS INCORPORATED	+6.95%	16.06B
NATERA, INC.	+81.08%	13.83B
TENET HEALTHCARE CORPORATION	+77.12%	12.84B
PURE HEALTH HOLDING	-26.49%	12.73B
REDE D'OR SÃO LUIZ S.A.	+2.68%	12.19B
UNIVERSAL HEALTH SERVICES, INC.	+18.05%	11.96B

Other Healthcare Facilities & Services